SPPI regnskab ude
-
Total GAAP revenue for 2012 was $267.7 million; pro forma revenue (including ex-US ZEVALIN
and FOLOTYN for the entire year) was $302 million.
GAAP Product revenues were up 41% and net income increased by 95% in 2012.
The Company reported GAAP Diluted EPS of $1.46 and Non-GAAP Diluted EPS of $1.42 compared to last year GAAP EPS of $0.84 and non-GAAP of $1.31.
FUSILEV unit volume was higher in the fourth quarter compared to the third quarter and end user sales trends are stable year-to-date.
Significant cost synergies have been achieved in a short period following the Allos acquisition. FOLOTYN shows strong sales growth in the most recent quarter.
The Company ended the year with a strong balance sheet with $143 million in cash, cash equivalents and investments after paying $133 million for the Allos acquisition, net of Allos' cash.
The Company expects revenues and operating income to increase in 2013.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind